Stefan Siebert

Jun 28, 2024 | ukmagsoc.org | Stefan Siebert |Lukasz Mierczak |Stan Trout |Parminder Sangha

Updated 03/04/2024A one day online course for anyone starting out in motor design. If you’re a new graduate, an experienced ICE engine designer starting work on electric vehicles, or an old hand looking for a refresher, this course will give you the basics. Leading cross-discipline experts from many different companies will teach the basics and speak from their own experiences gained over many years.

Jan 25, 2024 | nature.com | Stefan Siebert |Helena Marzo-Ortega

As in rheumatoid arthritis, achieving low disease activity or remission in psoriatic arthritis (PsA) remains a challenge and unmet need for many individuals. However, the complex pathogenesis, heterogeneity and varied tissue involvement in PsA mean that dedicated definitions and novel solutions are required for difficult-to-treat disease.

Jan 23, 2024 | acrjournals.onlinelibrary.wiley.com | Stefan Siebert |Laura Coates |Georg Schett |Friedrich-Alexander Universität Erlangen-Nürnberg

INTRODUCTION Psoriatic arthritis (PsA) is a chronic, heterogeneous, inflammatory disease with multiple musculoskeletal and dermatologic manifestations.1 Conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) are typically used as first-line treatments for patients with active peripheral arthritis involvement, while biologic DMARDs (bDMARDs) or targeted synthetic DMARDs are often used for those with an inadequate response to csDMARDs. Although advanced therapies, including...

Jul 13, 2023 | ard.bmj.com | Stefan Siebert |Helena Marzo-Ortega

http://orcid.org/0000-0002-1802-7311Stefan Siebert1, Helena Marzo-Ortega2 1 Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow, UK 2 Leeds Institute of Rheumatic and Molecular Medicine, University of Leeds, Leeds, UK Correspondence to Professor Stefan Siebert, Institute of Infection, Immunity & Inflammation, University of Glasgow, Glasgow, UK; stefan.siebert{at}glasgow.ac.uk Statistics from Altmetric.com Request Permissions If you wish to reuse any or all of...

Jul 6, 2023 | nature.com | Eleanor J. Barnes |Carl S. Goodyear |Michelle Willicombe |Stefan Siebert |John A Snowden |Peter Kelleher | +3 more

AbstractSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) immune responses and infection outcomes were evaluated in 2,686 patients with varying immune-suppressive disease states after administration of two Coronavirus Disease 2019 (COVID-19) vaccines. Overall, 255 of 2,204 (12%) patients failed to develop anti-spike antibodies, with an additional 600 of 2,204 (27%) patients generating low levels (<380 AU ml−1).